Linked Life Data

12416264

Source:http://linkedlifedata.com/resource/pubmed/id/12416264

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2002-11-5
pubmed:abstractText
The possible growth-inhibitory properties of the recently synthesized novel metabolite 1-(2,4-dihydrobenzoyl)-1-(4-hydroxyphenyl)ethylene (2-de-O-DMA) and six other metabolites of isoflavones were investigated and compared with those of the major isoflavones genistein, daidzein, and glycitein on human breast noncancer and breast and prostate cancer cell lines in vitro. The novel metabolite 2-de-O-DMA was found to be a more potent inhibitor than genistein on human breast cancer MCF-7, MDA-MB-468, and SK-BR-3 cells and breast noncancer MCF-10A cells. In prostate cancer cell lines, LNCaP and DU145, 2-de-O-DMA elicited a six- to sevenfold more potent inhibition than genistein. Flow cytometric analysis showed that 2-de-O-DMA and genistein blocked cells at the G2/M phase of the cell cycle. Genistein and 2-de-O-DMA led to apoptosis of a variety of cancer cell lines. The rapid response of growth inhibition induced by 2-de-O-DMA compared with genistein strongly suggests that the observed antiproliferation effects elicited by this novel metabolite are mediated via a biological pathway different from that induced by genistein. 2-de-O-DMA, a novel metabolite of isoflavone, could have a potential role in chemopreventive and chemotherapeutic treatment of hormonal breast and prostate cancers.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0163-5581
pubmed:author
pubmed:issnType
Print
pubmed:volume
42
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
224-32
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
A comparative study of growth-inhibitory effects of isoflavones and their metabolites on human breast and prostate cancer cell lines.
pubmed:affiliation
Ray Williams Institute of Paediatric Endocrinology and Diabetes and Metabolism, Children's Hospital, at Westmead, Westmead NSW 2145, Sydney, Australia.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't